Modality
Gene Editing
MOA
CGRPant
Target
PCSK9
Pathway
Tau
IPFCrohn'sRSV
Development Pipeline
Preclinical
~Apr 2014
→ ~Jul 2015
Phase 1
~Oct 2015
→ ~Jan 2017
Phase 2
~Apr 2017
→ ~Jul 2018
Phase 3
Oct 2018
→ Apr 2030
Phase 3Current
NCT08711627
1,185 pts·IPF
2022-05→2025-04·Recruiting
NCT06218436
2,457 pts·Crohn's
2018-10→2028-09·Completed
NCT05360866
718 pts·IPF
2019-10→2030-04·Completed
+1 more trial
5,826 total pts2 indications
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (4)
2025-04-2611mo agoPh3 Readout· IPF
2028-08-102.4y awayPh3 Readout· Crohn's
2028-09-282.5y awayPh3 Readout· Crohn's
2030-04-134.0y awayPh3 Readout· IPF
Trial Timeline
Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3
P3
Complet…
P3
Complet…
P3
Complet…
P3
Recruit…
Catalysts
Ph3 Readout
2025-04-26 · 11mo ago
IPF
Ph3 Readout
2028-08-10 · 2.4y away
Crohn's
Ph3 Readout
2028-09-28 · 2.5y away
Crohn's
Ph3 Readout
2030-04-13 · 4.0y away
IPF
RecruitingCompleted|StartCompletionToday
Trials (4)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08711627 | Phase 3 | IPF | Recruiting | 1185 | LiverFat |
| NCT06218436 | Phase 3 | Crohn's | Completed | 2457 | NT-proBNP |
| NCT05360866 | Phase 3 | IPF | Completed | 718 | NT-proBNP |
| NCT04796526 | Phase 3 | Crohn's | Completed | 1466 | DOR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Terafutibatinib | Pfizer | Phase 1/2 | CD38 | |
| Sotovorutinib | Pfizer | Approved | Aβ | |
| ABB-3060 | AbbVie | Phase 2 | LAG-3 | |
| Zanusertib | AbbVie | Approved | PCSK9 | |
| GIL-6239 | Gilead Sciences | Phase 2 | TNFα | |
| GIL-4361 | Gilead Sciences | Preclinical | PCSK9 | |
| Tezecilimab | Regeneron | Approved | IL-23 | |
| REG-2172 | Regeneron | Phase 1/2 | PCSK9 | |
| BMR-8377 | BioMarin | Phase 1/2 | PCSK9 | |
| INC-2432 | Incyte | Phase 2 | CD47 |